To investigate the potential of using PARP inhibitors to target the DDR pathway in lung cancer as a novel therapeutic approach, hATM KO isogenic cell lines were used to help elucidate the molecular mechanism associated with the synthetic lethality between hATM KO and PARPi treatment. This evidence concerns the gene PARP1 and lung cancer.